1	Association between virtual visits and health outcomes of people living with HIV: A cross-sectional
2	study
3	
4	Nadia Rehman <sup>1</sup> *, Lawrence Mbuagbaw <sup>1,2,3,4,5,6</sup> , Dominik Mertz <sup>1,7,8</sup> ¶, Giulia M. Muraca <sup>1, 9</sup> ¶, on behalf of
5	the Ontario HIV Treatment Network Cohort Study <sup>^</sup> and Realize <sup>^</sup> , Aaron Jones <sup>1,10,11</sup>
6	
7	<sup>1</sup> Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario,
8	Canada
9	<sup>2</sup> Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
10	<sup>3</sup> Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, Yaoundé,
11	Cameroon
12	<sup>4</sup> Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada
13	<sup>5</sup> Biostatistics Unit, Father Sean O'Sullivan Research. Centre, St Joseph's Healthcare, Hamilton, Ontario,
14	Canada
15	<sup>6</sup> Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape
16	Town, South Africa
17	<sup>7</sup> Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
18	<sup>8</sup> Department of Medicine, McMaster University, Hamilton, Ontario, Canada
19	<sup>9</sup> Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada
20	<sup>10</sup> Institute for Clinical Evaluative Sciences (IC/ES), McMaster University, Hamilton, Ontario, Canada
21	<sup>11</sup> Institute for Clinical Evaluative Sciences; IC/ES, University of Toronto, Ontario, Canada
22	

23

#### 24 \*Corresponding Author

- 25 Email: <u>rehmann@mcmaster.ca (NR)</u>
- 26
- 27 ¶ These authors contributed equally to this work.

28

- 29 ^ Membership of the Ontario HIV Treatment Network (OHTN) is provided in the Acknowledgments.
- 30 ^ Member of Realize is provided in the Acknowledgments.

## 32 Abstract

Background: Virtual care has been integrated as a modality of care in Ontario, yet its effectiveness for
 people living with HIV remains largely unexplored.

35 **Objectives:** We aimed to determine the association of visit modality (virtual, in-person, or both) on 36 adherence to antiretroviral therapy (ART), viral load, and quality of life (QOL) in people living with HIV 37 in Ontario, Canada.

Methods: We conducted a cross-sectional study using data from the 2022 Ontario HIV Treatment Network Cohort Study (OCS), collected during the COVID-19 pandemic when virtual visits were first introduced. Participants were grouped into three categories based on the mode of care: virtual, in-person, or a combination of both. Data were collected through self-reported questionnaires and medical records, with viral load data linked to Public Health Ontario Laboratories (PHOL). Logistic regression was used to examine the outcomes of optimal ART adherence and viral load suppression, and linear regression was used for quality of life (mental and physical) outcomes.

45 **Results:** In 2022, 1930 participants accessed HIV care in the OCS. Among them, 19.0% received virtual 46 care, 45.6% received in-person care, and 34.3% received care through virtual and in-person modalities. The 47 median age of the participants was 55 years (IOR: 45-62). In the multivariable logistic regression model, 48 virtual care was associated with an increased likelihood of optimal adherence to antiretroviral therapy 49 (Adjusted Odds Ratio (AOR) 1.30, 95% confidence interval (CI): 1.00-1.70) and an increased likelihood 50 of achieving viral load suppression (AOR 1.67, 95% CI:1.03-2.63). Moreover, combined virtual and in-51 person care is associated with an improved mental quality of life compared to in-person care (Adjusted 52 Mean difference (MD) - 0.960, 95% CI 0.052,1.869).

- 53 *Conclusion:* This study suggests virtual care is positively associated with adherence to antiretroviral
- 54 therapy (ART) and viral suppression within this context. However, future research is necessary to establish
- 55 causality and to assess the long-term effects of virtual care.
- 56 **Word count:** 2790

## 58 Introduction

59 HIV is a chronic health challenge, with 22,461 people living with HIV in Ontario, Canada, as of 60 2020 [1] This population faces a disproportionate burden due to socio-economic disparities and structural 61 barriers within the patient-provider relationship, which further complicates the continuity of HIV care, 62 contributing to sub-optimal retention in healthcare services and poor adherence to antiretroviral therapy 63 (ART) [2]. This results in detectable viral loads, increased opportunistic infections, and higher morbidity 64 and mortality rates [3-6]. Consistent access to ART and regular health assessments necessitates strong 65 patient retention in care, as highlighted by several studies [7-9]. Despite universal public coverage in 66 Ontario, challenges with retaining individuals in care persist. A fully accessible, patient-centred healthcare 67 system is essential to addressing these issues [10].

In 2021, Ontario, Canada, adopted virtual care in the healthcare sector to help mitigate the impact of the SARS-CoV-2 pandemic [12]. Virtual care is a health care model in which all clinical interactions between the practitioner and the patient are delivered using electronic mediums, such as video conferencing or audio digital tools, such as telephone [11]. Since 2022, Ontario has taken concrete measures to integrate virtual visits as complementary to traditional care. These measures include enhancing data security and privacy, addressing social and ethical considerations, establishing regulations for virtual healthcare, and introducing fee codes that enable physicians to bill for virtual visits [10, 12].

75 Virtual visits can help overcome barriers in HIV care by offering convenience, accessibility, and 76 affordability, potentially improving access to care and patient retention [13, 14]. However, virtual care has 77 several limitations, such as the inability to assess clinical conditions objectively, the lack of necessary 78 equipment, and the absence of physical interactions with physicians, which can lead to mistrust, multiple 79 appointments, and potential misdiagnosis [13]. Technology can also pose barriers for certain groups, 80 including older adults, individuals with lower literacy levels, and those from disadvantaged socio-economic 81 backgrounds [14]. The choice of virtual care compared to in-person visits may be influenced by physician 82 preferences and the significant discrepancies in Ontario's fee codes between comprehensive versus limited

care and telephone calls versus video visits [10, 15]. While some data suggest virtual care improves
retention in care, others report increased loss to follow-up [16]. As virtual care evolves, it is essential to
address disparities, prevent overuse, and consider unintended financial consequences with health equity
and ethical considerations in mind [10, 11, 16-18].

87 While virtual care has become a standard practice in Ontario [10], the evidence of its effectiveness 88 remains limited. We developed this study alongside the Ontario HIV Treatment Network (OHTN) [19], 89 utilizing the data from the Ontario HIV Treatment Network Cohort Study (OCS), the largest community-90 governed HIV cohort in North America [20]. The primary objective of the study was to assess whether 91 there were differences in adherence to antiretroviral therapy (ART), quality of life (QOL), and viral load 92 among people living with HIV in Ontario, Canada, based on whether they used virtual or in-person 93 appointments with an HIV care physician. The secondary objective of the study was to evaluate the 94 differences in health outcomes (adherence to ART, QOL, and viral load) among people living with HIV 95 from various socio-demographic and health-related factors in Ontario, as virtual care may affect certain 96 groups differently.

## 97 Methods

## 98 Study Design

We conducted a cross-sectional study using data from participants in the OCS in 2022.

### 100 Setting

101 The OCS is a multi-site clinical cohort of people receiving HIV care in Ontario, Canada's most 102 populous province (population: 13.6 million). Recruitment occurs at ten participating sites, including 103 outpatient clinics in hospitals and community-based practices. The cohort has been described elsewhere 104 [21].

## 105 Stakeholder Engagement

106 To achieve our study objectives, we established a community advisory board (CAB) in 107 collaboration with Realize, a Canadian charitable organization working with people living with HIV and related organizations. The CAB comprises representatives from various key populations of people living 108 109 with HIV, enhancing the external validity of our project, bolstering individual and community capacity, 110 and ensuring the effective implementation of our research findings [22, 23]. We convened a meeting with 111 the CAB to seek their insights on the relevance of the research question, the socio-demographic factors 112 involved, and the correlation with the health conditions of people living with HIV. The CAB also actively 113 interpreted the findings and collaborated on a dissemination plan for our research outcomes.

### 114 Data Sources

115 Clinical data are collected during routine follow-up visits, sourced from clinic records via manual 116 chart abstractions or computerized medical record systems, and record linkage with Public Health Ontario 117 Laboratories (PHOL), the sole provider of such testing provincially. Additionally, annual interviews are 118 conducted using standardized questionnaires to gather socio-demographic and psycho-social-behavioural 119 information. All participants provide written informed consent, and the cohort design and consent forms 120 are approved by the University of Toronto Research Ethics Boards (REBs) and REBs at each participating 121 site [21]. Data was accessed on November 23, 2023. And the data was in de-identified form.

## 122 **Population**

Eligible participants for our study are those aged 16 years or older who visited their HIV physician using any of the three modalities of care (virtual, in-person visits, or both virtual and in-person care) in 2022 and completed the OCS questionnaire. Participants with incomplete information on the type of care received were excluded.

## 127 Measures/Outcomes

## 128 **Primary outcome**

Adherence to ART was assessed using self-reported data from the standardized OCS questionnaire. For this study, we aimed to dichotomize adherence into optimal adherence ( $\geq$ 95%) and suboptimal adherence (<95%). We considered optimal adherence as participants who reported never missing a dose or missing a dose more than three months ago. In contrast, suboptimal adherence included those who missed doses within the past week, 1–4 weeks ago, 1-3 months, or responded with "don't know." These classifications were established in consultation with HIV specialists from a dedicated HIV care facility.

## 135 Secondary Outcomes

Viral load suppression was defined as  $\leq 40$  copies/mL, indicating virological suppression (stable viral load). Any value > 40 copies/mL is considered virologically unsuppressed and unfavourable. QOL was assessed using the Short Form 12-item Health Survey (version 2), which includes two components: the Mental Component Summary Score (MCS) and the Physical Component Summary Score (PCS), both of which are reported separately [24].

## 141 Variables

### 142 **Primary exposure**

We categorized the HIV care that the patients received into three mutually exclusive categories: i).
In-person care at the clinic ii). Virtual care either by telephone or video call, iii). Combination of in-person and virtual forms of care.

## 146 **Demographic and clinical variables**

Baseline demographic and clinical data were extracted from the 2022 OCS questionnaire. Due to multiple categories in the OCS data, some of which were not information-rich, we consolidated them into meaningful categories for our study. Data missing values are reported separately in Table 1, which details the baseline characteristics.

For demographic variables, we combined sex (female versus male) and sexual orientation (men who have sex with men (MSM) vs non-MSM) to derive a single variable named sex, compromising three categories: females, male MSM, and male non-MSM and relationship status categorized as stable (married, living common-law, living in a committed relationship) vs unstable relationship (widowed, separated/divorced, single).

Clinical variables were extracted on the following health conditions: alcohol use disorder syndrome use was defined as on the Alcohol Use Disorder Identification Test (AUDIT-10) with harmful alcohol measured from 10- items (a score of  $\geq$ 8 regardless of gender/sex) [25], depression measured by the Patient Health Questionnaire (PHQ) scale with nine items [26], smoking cigarettes/tobacco defined as heavy smokers versus light smokers (heavy smokers defined as people who have been smoking at least 20 cigarettes daily) [27]; and diagnosis of mental health comorbidities was based on self-report in the OCS question.

We used a revised 10-item HIV-related stigma scale categorized into four major components of HIV-related stigma: personalized stigma, worries about disclosure of status, negative self-image, and sensitivity to public reactions about HIV status. Individuals who responded with "agree" and "strongly agree" were identified as experiencing stigma in at least one of the four components [28].

167 Sample size calculations:

The study was planned with a sample size of 1,930 subjects, providing 80% power to detect a difference of 20% or greater between suboptimal and optimal adherence to ART between the groups. [29]. The Type I error probability associated with the test of the null hypothesis is 0.05 for the two-tailed chi-

squared statistic. (PS: Power and Sample Size Calculation version 3.1.2, 2014 by W.D. Dupont & W.D.
Plummer Jr).

## 173 Data analysis:

174 Statistical analysis was performed using R software version 4.4.1. We used descriptive statistics to 175 analyze participants' characteristics, reporting proportions for categorical variables and median with 176 interquartile range (IQR) for continuous variables. The latter were compared using the Wilcoxon rank-sum 177 test, as these scores are not normally distributed [30]. Chi-square tests were used for categorical variables.

The variable selection was guided by a priori knowledge of their association with adherence to ART, considering collinearity between variables and potential confounding. Age, sex, ethnicity, employment, education level, substance use, stigma and living alone were included in all models as potential confounders, regardless of their significance [3, 11, 31, 32]. To select the remaining variables for our models, we used the 'majority selection method' and selected the variables that appeared in at least half of the models [33]

## 184 **Regression Analysis:**

We conducted a logistic regression analysis for dichotomous outcomes (adherence to ART and suppression of the viral load) and a multiple linear regression for continuous outcomes (quality of life). To check the model fit for multiple linear regression models, we used a pooled  $R^2$ . The dichotomous outcomes are reported as odds ratio (OR) and 95% confidence intervals, and continuous outcomes are reported as mean differences with 95% confidence intervals. The statistically significant level is set when the *p*-value is <0.05 or the 95% CI excludes the null value.

191 The OCS questionnaire had data missing at random (MAR), so we performed ten imputations for 192 each model and combined the results using Rubin's rules [33, 34].

### 193 Subgroup analysis

We performed subgroup analysis to assess the differences in health outcomes (adherence to ART, quality of life and viral load) of people living with HIV from different socio-demographics in Ontario, Canada. The data from the OCS Questionnaire 2022 was collected during the COVID-19 pandemic when virtual visits were first introduced. [15]. Since government COVID-19 policies and users' preferences may have impacted decisions to attend virtual visits, we compared outcomes during and after lockdowns [35].

## 199 **Results**

200 In 2022, the OCS questionnaire was completed by 2155 people, with 1930 providing details on the 201 type of care they received (S 1 Fig). That year, 1021/1930 (53%) HIV care visits were conducted by 202 telephone, 23/1930 (1.2%) via computer visits, and 1563/1930 (80%) were provided through in-person 203 visits. The median age of the participants was 55 years [IQR: 45-62]. In 2022, stratum-specific proportions 204 of participants in the three different types of care modalities (i.e. in-person, virtual and participants who 205 used both in-person and virtual care) varied by participant characteristics (Table 1). Notably,1493/1930 206 (78%) participants were men, with the majority being MSM, compromising 58.6% (1131/1930). Regarding 207 care modality preferences, in-person visits were most preferred across all genders. Table 1 provides the 208 statistical relationship between all other variables and the type of care.

 Table 1. Comparison of baseline characteristics between participants who accessed HIV care

 through virtual, in-person or both virtual and in-person care in Ontario, Canada, in 2022

Characteristics	In-person care n (%)	Virtual care n (%)	Virtual and in- person care n (%)	p-value
No. of participants	900	367	663	
Median age [Q1-Q3]	55 [44-63]	56 [46-62]	55 [45-62]	0.772
Sex				

Female	233 (25.9)	60 (16.3)	132 (20.2)	< 0.001
Male MSM <sup>a</sup>	459 (50.8)	253 (70.0)	419 (63.4)	
Male non-MSM	203 (22.6)	49 (13.4)	110 (16.2)	
Missing	5 (0.55)	5 (1)	2 (0.3)	
Race				
White	478 (53.1)	252 (68.7)	442 (66.6)	< 0.001
Black	263 (29.3)	55 (14.9)	130 (19.6)	
Other	159 (17.6)	60 (16.3)	91 (13.7)	
Region				
Eastern Ontario	127 (14.1)	24 (6.5)	22 (3.3)	< 0.001
Northern Ontario	18 (2)	5 (1.4)	2 (0.3)	
Southwestern Ontario	99 (11)	62 (16.9)	174 (26.2)	
Toronto	656 (72.8)	276 (75.2)	465 (70.1)	
Education				
Elementary	25 (2.7)	10 (2.7)	14 (2.1)	0.246
High school	239 (26.5)	126 (34.3)	224 (33.7)	
College	210 (23.3)	64 (17.4)	139 (20.9)	
Higher education	363 (40.3)	162 (44.1)	284 (42.8)	
Missing	63 (7)	5 (1.4)	2 (0.3)	
Employment status				
Employed	433 (48.1)	182 (49.6)	327 (49.3)	0.285
Unemployed	463 (51.4)	182 (49.6)	336 (50.7)	
Missing	4 (0.4)	3 (0.8)	0 (0)	
Gross annual income				
<50,000	374 (41.5)	144 (39.2)	280 (42.2)	0.287

< 50,000-70,000	103(11.4)	45 (12.2)	75 (11.3)	
< 70,000-80,000	121 (13.4)	41 (11.1)	76 (11.4)	
>100,000	173 (19.2)	94 (25.6)	150 (22.6)	
Missing	129 (14.3)	43 (11.7)	82 (12.3)	
Stable relationship				
Yes	376 (41.6)	154 (42.0)	246 (37.1)	0.17
Unstable relationship	521 (57.8)	212 (57.8)	417 (62.9)	
Missing	3 (0.3)	1 (0.3)	0 (0)	
Adherence to ART				
< 95%	295 (32.7)	137 (37.3)	247 (37.3)	0.014
≥95%	600 (66.6)	225 (61.3)	412 (62.1)	
Missing	5 (0.5)	5 (1.3)	4 (0.6)	
Mental health conditions				
Depression	197 (21.8)	44 (12.0)	167 (25.1)	0.190
Alcohol use disorder	67 (7.4)	34 (9.2)	65 (9.8)	
syndrome <sup>d</sup>				
No	824 (91.6)	331 (90.1)	598 (90.1)	0.248
Yes				
Stigma				
Stigmatized	125 (13.8)	12 (3.28)	92 (13.8)	0.5083
Not stigmatized	8 (0.88)	2 (0.54)	7 (1.05)	
Missing	767 (85.2)	353 (96.1)	564 (85.0)	
Quality of life				
MCS	50.2 [41.25; 57.00]	49.2 [40.82;55.32]	50.9 [38.67;56.30]	0.403
	]			

PCS	53.1 [43.8;57.2]	53.5 [44.87;57.35]	52.7 [43.57;56.70]	0.548
Viral load				
$\leq 40$	766 (85.0)	336 (91.6)	579 (87.3)	0.02
> 40	104 (11.5)	26 (7.0)	70 (10.5)	
Missing	30 (0.5)	5 (1.4)	14 (2.1)	
<sup>a</sup> Men who report having	g sex with other men			
<sup>b</sup> Immigrant > 10 years				
<sup>c</sup> Immigrant <10 years				
<sup>d</sup> Alcohol Use Disorder	Identification Test (AUDI)	Γ-10)		

## 210 Adherence to ART

209

211 There were 600 (66.6%) participants with optimal ART adherence. According to our logistic

212 regression analysis, the odds of adherence to ART were higher for participants who used virtual care than

in-person care in both adjusted and unadjusted analysis (OR 1.47 %, 95% CI 1.14, 1.89; AOR 1.31%,

214 95% CI 1.00-1.71).

## 215 Viral load

There were 766 (85.0%) participants with adequate viral load suppression. The odds of viral load suppression were higher in the virtual group than in person-care (OR 1.81, 95%CI: 0.69-2.85; AOR 1.67,

218 95% CI:1.03-2.63).

## 219 Quality of life

220 The average MCS score was 50.2 and, the average PCS score was 53.1. According to our

adjusted multiple regression model, combined virtual and in-person care is associated with an improved

222 quality of life in terms of MCS compared to in-person care (Mean difference (MD) -0.90, 95 % CI -

223 2.10,0.30; adjusted MD 0.960, 95% CI 0.052,1.869). All results can be found in Table 2.

Ontario, Canada					
Variable	Unadjusted Effect	p-value	Adjusted Effect	p-value	
	Estimates (95%CI)		Estimates (95%		
			CI)		
Adherence to ART (OR)					
In-person(ref)	1.00 (ref)		1.00 (ref)		
Virtual and in-person	1.23 (0.99, 1.52)	0.05	1.03 (0.82, 1.30)	0.743	
Virtual	1.47 (1.14, 1.89) *	0.003	1.30 (1.00, 1.70) *	0.048	
Viral load (OR) <40 ml/cc pi	referred				
In-person(ref)	1.00 (ref)		1.00 (ref)		
Virtual and in-person care	1.13 (0.52, 1.56)	0.431	1.08 (0.76, 1.53)	0.651	
Virtual care	1.81 (0.69, 2.85)	0.010	1.67 (1.03, 2.63)	0.0374	
<sup>1</sup> MCS					
In-person visit	0 (ref)		0 (ref)		
Virtual and in-person	-0.90 (-2.10,0.30)	0.142	0.96 (0.05,1.86) *	0.038	
Virtual	-0.53 (-1.99, 0.92)	0.469	0.13 (-0.94, 1.2)	0.810	
<sup>2</sup> PCS					
In-person visit	0 (ref)		0 (ref)		
Virtual and in-person	-0.90 (-2.10, 0.30)	0.142	-0.91 (-1.24,0.85)	0.711	
Virtual	-0.53 (-1.99, 0.92)	0.469	0.09 (-1.14,1.32)	0.811	
<sup>a</sup> Adjusted for covariates					
* Statistically significant					
<sup>1</sup> Mental Component Summa	rv Score				

## 226 Sub-group analysis

Among patients whose physicians based their preference of the type of care mode on the viral load, receiving in-person care was associated with lower odds of adherence to ART than receiving virtual care (OR 0.29, 95% CI 0.10-0.83; AOR 0.28, 95% CI 0.09-0.86).

- Among patients whose physicians based their preference of the type of care mode on the viral load,
- the receipt of both virtual and in-person care was associated with decreased MCS quality of life compared
- with participants who used the in-person care mode. (MD -5.60, 95% CI -9.46 1.75; Adjusted MD -3.75,
- 233 95% CI -6.51—0.99). Detailed findings are provided in S 1 Table.

## 234 **Discussion**

This study examined three types of care used in the OCS cohort 2022: in-person, virtual and patients using both. Patients across all demographic and medical backgrounds used virtual care options. In this cohort, the participants who used virtual care mode most frequently were 51-60, perhaps suggesting that older patients are comfortable with technology. However, the predominant mode of care within this cohort remained in-person visits. In this cohort consisting of participants living with HIV in Ontario, we observed that participants with better adherence to ART and with viral load suppression preferred the virtual care, and participants with a higher MCS quality of life utilized both virtual and in-person care.

Sex was the strongest predictor of the type of care used, with male MSM favouring in-person care. Participants residing in Toronto preferred virtual care compared to those in Eastern Ontario, though these groups overlap, as many male MSM in Toronto might be the same individuals. Participants with any form of depression tended to use both virtual and in-person care, possibly choosing their care mode based on the severity of their depression at the time of the visit.

Our subgroup analysis based on physicians' preference for the type of visit by viral load revealed decreased ART adherence within the virtual care group. However, the primary analysis showed a 30% improvement in ART adherence among participants using virtual visits compared to in-person groups. This

suggests physicians preferred in-person visits for patients with unsuppressed viral lows and poor ARTadherence.

252 This study has several limitations that prevent drawing definitive conclusions. The cross-sectional 253 design prevents us from establishing causality, making it difficult to determine whether virtual care directly 254 influences HIV related-health outcomes. Additionally, the data analyzed is from 2022, a period when virtual 255 care was newly introduced and still in the early stages of implementation, including the development of 256 specific standards, equipment selection and user training [38, 49]. Moreover, during the study period, 257 decisions regarding the type of care were often influenced by the government's lockdown orders rather than 258 the preferences of physicians or patients [38]. Non-response bias further restricts the conclusion of 259 differences between care modes. Furthermore, challenges related to optimizing virtual care usability and 260 user-friendliness remain unexplored.

The OCS employs a standardized questionnaire developed in consultation with the OHTN, CAB and the governance committees. However, the primary outcome—ART adherence—is based on selfreporting, which is subjective and prone to recall bias [3].

The study's findings are influenced by selection and information biases, as participants are predominantly aged 51-55, with high incomes and stable housing. This limits the understanding of agerelated acceptance and barriers. The cohort mainly includes highly engaged individuals, which doesn't fully represent overall care engagement. Younger, tech-savvy individuals and rural populations are underrepresented in this cohort, limiting insights into the broader applicability of virtual care and ruralurban differences [32, 35].

270 Despite potential sample biases, the study's large sample size and real-time data collection enhance271 the robustness of its findings.

The study was guided by a CAB, whose input was integrated throughout the study, including their feedback on result interpretation. Collaborating closely with experienced HIV care physicians provides

valuable insights into clinical practice dynamics and potential implementation strategies based on studyoutcomes [36].

#### 276 Future research

277 It's essential to recognize that this research is exploratory, and the COVID-19 pandemic 278 lockdowns confound it. Future research should explore the impact of virtual visits on HIV care and improve 279 access. Key issues include standards, licensure, equity, and payment systems. Virtual visits can help address 280 physician shortages, especially in rural areas, by offering flexible, quality care. Expanding virtual care to 281 all socioeconomic groups is vital. Redesigning care based on necessity and feasibility could enhance access 282 and outcomes [37, 38]. Future studies should assess system-wide effects, user satisfaction, cost-283 effectiveness, and physician views while linking OCS data with ICES data to analyze clinical outcomes 284 and patient preferences.

## 285 Conclusion

In our study in the OCS 2022 of people living with HIV, participants with better self-reported adherence to ART and a suppressed viral load preferred virtual care as compared to in-person care. Moreover, participants who used both virtual and in-person care reported higher mental health quality of life.

#### **Data Statement**

The data is obtained from OHTN from the OCS study. It is unethical for the authors to share the data set
publicly. However, the data request can be made directly with OHTN by submitting a <u>Research Application</u>
<u>Process (RAP).</u>

## 294 Declaration of Conflicting Interests

295 The author(s) declared no potential conflicts of interest.

## 296 Funding

297 This study did not receive any funding.

### 298 Authors' contributions

A.J., L.M., and N.R. contributed to the study's concept. The study design was finalized after feedback from
all the authors (L.M., N.R., M.G., D.M., and A.J.). OHTN provided the final approval and the data. N.R.
and A.J. conducted the analysis. N.R. prepared the original draft. All authors critically revised, approved
and agreed to be held accountable for all aspects of this work. Realize provided support and guidance for
CAB recruitment, consultation on community engagement and study design.

304

#### 305 Acknowledgements

The OHTN Cohort Study Team consists of Dr. Ann Burchell (Interim Principal Investigator), St. Michael's 306 307 Hospital and University of Toronto; Dr. Anita Benoit (Co-investigator), University of Toronto; Dr. 308 Lawrence Mbuagbaw (Co-Investigator), McMaster University; Dr. Sergio Rueda, CAMH and University 309 of Toronto; Dr. Gordon Arbess, St. Michael's Hospital; Dr. Jeffrey Cohen, Windsor Regional Hospital; Dr. 310 Curtis Cooper, Ottawa General Hospital; Dr. Maheen Saeed, University of Ottawa Health Services; Dr. 311 Mona Loutfy, Maple Leaf Medical Clinic; Dr. David Knox, Maple Leaf Medical Clinic; Dr. Nisha Andany, 312 Sunnybrook Health Sciences Centre; Dr. Sharon Walmsley, Toronto General Hospital; Dr. Michael 313 Silverman, St. Joseph's Health Care; Ms. Tammy Bourque, Health Sciences North; Wangari Tharao, 314 Women's Health in Women's Hands Community Health Centre; Holly Gauvin, Elevate NWO; Dr. Jeffrey 315 Craig, Lakeridge Health, Dr. Jorge Martinez-Cajas, Kingston Health Sciences Centre, and Dr. Marek 316 Smijea, Hamilton Health Sciences Centre.

We gratefully acknowledge all of the people living with HIV who volunteered to participate in the OHTN
Cohort Study and the work and support of the OCS Governance Committee: (Dane Record, Jasmine
Cotnam, Barry Adam, Adrian Betts, Cornel Gray, Ruth Cameron, Rodney Rousseau, Mary Ndung'u,
Viviana Santibañez, YY Chen, Jason Brophy, Aaron Bowerman), OCS Scientific Steering Committee (Dr.
Sergio Rueda, Dr. Barry Adam, Dr. David Brennan, Dr. Trevor Hart, Dr. Lance McReady, Dr. Lawrence
Mbuagbaw, Dr. Anita Benoit, Dr. Mona Loutfy, Dr. Curtis Cooper, Dr. Sean Hillier, Mr. Pierre Giguere,
Dr. Kelly O'Brien).

- 324 We thank all the interviewers, data collectors, research associates and coordinators, nurses and physicians
- 325 who provide support for data collection and extraction. The authors wish to thank the OCS staff for data
- 326 management, IT support, and study coordination: Lydia Makoroka, Lucia Light, Nahid Qureshi, Namita
- 327 Prabhu, Tsegaye Bekele, and Mustafa Karacam.
- 328 We also acknowledge the Public Health Laboratories, Public Health Ontario, for supporting record linkage
- 329 with the HIV viral load database.
- 330 The OHTN Cohort Study is supported by the Ontario Ministry of Health and Long-Term Care.
- 331 The opinions, results and conclusions are those of the authors and no endorsement by the Ontario HIV
- 332 Treatment Network or Public Health Ontario is intended or should be inferred.

334

#### 336 References 337 The Ontario HIV Epidemiology and Surveillance Initiative. Current Trend for HIV in 338 1. 339 Ontario: OHESI; 2023 [Available from: https://www.ohesi.ca]. Wilton J, Liu J, Sullivan A, Rachlis B, Marchand-Austin A, Giles M, et al. Trends in HIV 340 2. 341 care cascade engagement among diagnosed people living with HIV in Ontario, Canada: A retrospective, population-based cohort study. PLoS One. 2019;14(1):e0210096. 342 343 Rachlis B, Burchell AN, Gardner S, Light L, Raboud J, Antoniou T, et al. Social 3. 344 determinants of health and retention in HIV care in a clinical cohort in Ontario, Canada. AIDS 345 Care. 2017;29(7):828-37. Abebe Moges N, Olubukola A, Micheal O, Berhane Y. HIV patients retention and 346 4. attrition in care and their determinants in Ethiopia: a systematic review and meta-analysis. BMC 347 348 Infect Dis. 2020;20(1):439. 349 Benoit AC, Burchell AN, O'Brien KK, Raboud J, Gardner S, Light L, et al. Examining 5. 350 the association between stress and antiretroviral therapy adherence among women living with 351 HIV in Toronto, Ontario. HIV Res Clin Pract. 2020;21(2-3):45-55. 352 Mbuagbaw L, Sivaramalingam B, Navarro T, Hobson N, Keepanasseril A, Wilczynski 6. 353 NJ, et al. Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic 354 review of high quality studies. AIDS Patient Care and STDs. 2015;29(5):248-66. Mbuagbaw L, Hajizadeh A, Wang A, Mertz D, Lawson DO, Smieja M, et al. Overview 355 7. 356 of systematic reviews on strategies to improve treatment initiation, adherence to antiretroviral 357 therapy and retention in care for people living with HIV: part 1. BMJ Open. 2020;10(9):e034793. 358 Yehia BR. Stephens-Shields AJ, Fleishman JA, Berry SA, Agwu AL, Metlay JP, et al. 359 8. The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression. 360 PLOS One. 2015;10(6):e0129376. 361 Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: 362 9. updates, goals, and recommendations for the future. AIDS Res Ther. 2016;13:35. 363 Government of Ontario. Virtual Care 1: Comprehensive and Limited Virtual Care 364 10. Services 2022 [cited 2023 24th August 2023]. Available from: 365 366 https://www.ontario.ca/document/education-and-prevention-committee-billing-briefs/virtualcare-1-comprehensive-and-limited#section-2. 367 Heyworth L, Kirsh S, Zulman D, Ferguson JM, Kizer KW. Expanding access through 368 11. virtual care: The VA's early experience with Covid-19. NEJM Catalyst Innovations in Care 369 370 Delivery. 2020. 371 Government of Canada. Pan-Canadian virtual care priorities in response to COVID-19 12. 372 2021. 373 13. Gomez T, Anava YB, Shih KJ, Tarn DM, A Qualitative Study of Primary Care Physicians' Experiences With Telemedicine During COVID-19. The Journal of the American 374 375 Board of Family Medicine. 2021;34(Supplement):S61-S70. 376 14. Glauser W. Virtual care is here to stay, but major challenges remain: CMAJ. Canadian 377 Medical Association Journal. 2020;192(30):E868-E9. 378 15. Government of Ontario. OHIP Info Bulletins. 2022.

379 Budak JZ, Scott JD, Dhanireddy S, Wood BR. The Impact of COVID-19 on HIV Care 16. 380 Provided via Telemedicine-Past, Present, and Future. Curr HIV/AIDS Rep. 2021;18(2):98-104. McGinnis KA, Skanderson M, Justice AC, Akgun KM, Tate JP, King JT, Jr., et al. HIV 381 17. 382 care using differentiated service delivery during the COVID-19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs. J Int AIDS Soc. 2021;24 Suppl 6:e25810. 383 Dorn SD. Backslide or forward progress? Virtual care at U.S. healthcare systems beyond 384 18. the COVID-19 pandemic. NPJ Digit Med. 2021;4(1):6. 385 386 19. The Ontario HIV Treatment Network. HIV in Ontario 2023 [Available from: 387 https://www.ohtn.on.ca. 20. Ontario HIV treatment Network OCS (OHTN Cohort Study). Research Policies 388 389 [Available from: https://ohtncohortstudy.ca/wp-content/uploads/2022/12/OCS-Research-390 Policies 6-Oct-2022 Clean.pdf. 391 Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, et al. Cohort 21. 392 profile: the Ontario HIV Treatment Network Cohort Study (OCS). Int J Epidemiol. 393 2013;42(2):402-11. 394 Lo Hog Tian JM, Watson JR, Deyman M, Tran B, Kerber P, Nanami K, et al. Building 22. 395 capacity in quantitative research and data storytelling to enhance knowledge translation: a 396 training curriculum for peer researchers. Research Involvement and Engagement. 2022;8(1):69. 397 Cashman SB, Adeky S, Allen III AJ, Corburn J, Israel BA, Montaño J, et al. The power 23. 398 and the promise: working with communities to analyze data, interpret findings, and get to 399 outcomes. American Journal of Public Health. 2008;98(8):1407-17. Ding X, Abner EL, Schmitt FA, Crowley J, Goodman P, Kryscio RJ. Mental Component 400 24. 401 Score (MCS) from Health-Related Quality of Life Predicts Incidence of Dementia in U.S. Males. 402 J Prev Alzheimers Dis. 2021;8(2):169-74. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol 403 25. 404 consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification 405 406 Test. Arch Intern Med. 1998;158(16):1789-95. 407 Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a brief 26. 408 self-report instrument: sensitivity to change of the Patient Health Ouestionnaire (PHO-9). Journal 409 of Affective Disorders. 2004;81(1):61-6. 410 Machado RC, Vargas HO, Baracat MM, Urbano MR, Verri Jr WA, Porcu M, et al. N-27. 411 acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial. Brazilian Journal of Psychiatry. 2020;42:519-26. 412 Etowa J, Hannan J, Babatunde S, Etowa EB, Mkandawire P, Phillips JC. HIV-related 413 28. stigma among black mothers in two north American and one African cities. Journal of Racial and 414 Ethnic Health Disparities. 2020;7:1130-9. 415 Cote J, Godin G, Ramirez-Garcia P, Rouleau G, Bourbonnais A, Gueheneuc YG, et al. 416 29. 417 Virtual intervention to support self-management of antiretroviral therapy among people living with HIV. J Med Internet Res. 2015;17(1):e6. 418 419 Bridge PD, Sawilowsky SS. Increasing physicians' awareness of the impact of statistics 30. 420 on research outcomes: comparative power of the t-test and Wilcoxon rank-sum test in small samples applied research. Journal of Clinical Epidemiology. 1999;52(3):229-35. 421 Logie C, James L, Tharao W, Loutfy M. Associations between HIV-related stigma, racial 422 31. 423 discrimination, gender discrimination, and depression among HIV-positive African, Caribbean, 424 and Black women in Ontario, Canada. AIDS patient care and STDs. 2013;27(2):114-22.

425 32. Burchell AN, Gardner S, Light L, Ellis BM, Antoniou T, Bacon J, et al. Implementation 426 and operational research: engagement in HIV care among persons enrolled in a clinical HIV cohort in Ontario, Canada, 2001–2011. JAIDS Journal of Acquired Immune Deficiency 427 428 Syndromes. 2015;70(1):e10-e9. 429 Heymans MaE I. Applied missing data analysis with SPSS and (R) Studio. Heymans and 33. 430 Eekhout;2019. 34. Van Buuren S. Flexible imputation of missing data: CRC press; 2018. 431 432 35. Ferguson JM, Jacobs J, Yefimova M, Greene L, Heyworth L, Zulman DM. Virtual care 433 expansion in the Veterans Health Administration during the COVID-19 pandemic: clinical 434 services and patient characteristics associated with utilization. J Am Med Inform Assoc. 435 2021;28(3):453-62. 436 Realize. Fostering positive change for people living with HIV and other episodic 36. disabilities. 2023 [Available from: http://forum.realizecanada.org/about-us/. 437 Lawal FJ, Omotayo MO, Lee TJ, Srinivasa Rao ASR, Vazquez JA. HIV Treatment 438 37. 439 Outcomes in Rural Georgia Using Telemedicine. Open Forum Infect Dis. 2021;8(6):ofab234. León A, Cáceres C, Fernández E, Chausa P, Martin M, Codina C, et al. A new 440 38. 441 multidisciplinary home care telemedicine system to monitor stable chronic human 442 immunodeficiency virus-infected patients: a randomized study. PLoS One. 2011;6(1):e14515. 443

# 444 Supporting information

- 445 **S 1 Fig.** Study flow diagram of participants who received HIV care in 2022.
- 446 **S 1 Table.** Multivariable subgroup regression analysis of HIV-related outcomes of people receiving care
- 447 in Ontario, Canada



Fig 1. Study flow diagram of participants who received HIV care in 2022.

# Figure